The triptan drug class dominates the market for approved prescription acute treatments for migraine. Despite the array of approved triptan options, most of them generic, new reformulations have launched over the past few years that provide incremental advantages over the standard of care, and novel nontriptan alternatives appear on the horizon. This content explores how newer therapies have fared in this highly generic market and provides important context for new players entering a large, still underserved, and commercially promising arena.
- What patient shares do key therapies and brands garner by line of therapy in the acute treatment of newly diagnosed migraine patients? What are the quarterly trends in the prescribing of acute treatments among recently treated and newly diagnosed migraine patients?
- How have therapies for the acute treatment of migraine been integrated into the treatment algorithm?
- What proportion of migraineurs receive prescription drug acute therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of acute treatment within two years of diagnosis?
- What percentage of migraine patients are treated with acute treatment monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among migraine patients treated with prescription acute therapies?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Geographies: United States
Key drugs covered: sumatriptan (all formulations), Onzetra Xsail, eletriptan, frovatriptan, rizatriptan oral/ODT, Treximet, zolmitriptan oral/ODT, Zomig Nasal Spray, dihydroergotamine (nasal/injectable), Cambia
- Migraine - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Acute)
- Treatment Algorithms-Claims Data Analysis-Migraine-Acute Treatment-August 2018
Author(s): Niyati Khetarpal, Ph.D
"Niyati Khetarpal is a business insights analyst on the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope proteins.”